109 related articles for article (PubMed ID: 2874226)
1. Buspirone analogues. 2. Structure-activity relationships of aromatic imide derivatives.
New JS; Yevich JP; Eison MS; Taylor DP; Eison AS; Riblet LA; VanderMaelen CP; Temple DL
J Med Chem; 1986 Aug; 29(8):1476-82. PubMed ID: 2874226
[TBL] [Abstract][Full Text] [Related]
2. Buspirone analogues. 1. Structure-activity relationships in a series of N-aryl- and heteroarylpiperazine derivatives.
Yevich JP; Temple DL; New JS; Taylor DP; Riblet LA
J Med Chem; 1983 Feb; 26(2):194-203. PubMed ID: 6131130
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and anxiolytic activity of N-substituted cyclic imides (1R*,2S*,3R*,4S*)-N-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,3- bicyclo[2.2.1]heptanedicarboximide (tandospirone) and related compounds.
Ishizumi K; Kojima A; Antoku F
Chem Pharm Bull (Tokyo); 1991 Sep; 39(9):2288-300. PubMed ID: 1687114
[TBL] [Abstract][Full Text] [Related]
4. Comparative neuropharmacology of buspirone and MJ-13805, a potential anti-anxiety drug.
McMillen BA; Mattiace LA
J Neural Transm; 1983; 57(4):255-65. PubMed ID: 6140299
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats.
Kääriäinen TM; Lehtonen M; Forsberg MM; Savolainen J; Käenmäki M; Männistö PT
Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):50-8. PubMed ID: 17971064
[TBL] [Abstract][Full Text] [Related]
6. Selective effects of buspirone and molindone on dopamine metabolism and function in the striatum and frontal cortex of the rat.
McMillen BA; McDonald CC
Neuropharmacology; 1983 Mar; 22(3):273-8. PubMed ID: 6133232
[TBL] [Abstract][Full Text] [Related]
7. Preclinical pharmacology of buspirone hydrochloride.
Skolnick P; Paul SM; Weissman BA
Pharmacotherapy; 1984; 4(6):308-14. PubMed ID: 6151169
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological properties of SM-3997: a new anxioselective anxiolytic candidate.
Shimizu H; Hirose A; Tatsuno T; Nakamura M; Katsube J
Jpn J Pharmacol; 1987 Dec; 45(4):493-500. PubMed ID: 2895201
[TBL] [Abstract][Full Text] [Related]
9. Similar pharmacological properties of 8-OH-DPAT and alnespirone (S 20499) at dopamine receptors: comparison with buspirone.
Protais P; Lesourd M; Comoy E
Eur J Pharmacol; 1998 Jul; 352(2-3):179-87. PubMed ID: 9716353
[TBL] [Abstract][Full Text] [Related]
10. Effect of buspirone on rat plasma prolactin levels and striatal dopamine turnover.
Meltzer HY; Simonovic M; Fang VS; Gudelsky GA
Psychopharmacology (Berl); 1982; 78(1):49-53. PubMed ID: 6128756
[TBL] [Abstract][Full Text] [Related]
11. Effects of carbamazepine and ipsapirone on turnovers of monoamines in the rat brain.
Nibuya M; Kanba S; Kinoshita N; Suzuki E; Yagi G; Nakaki T; Kato R
Jpn J Psychiatry Neurol; 1991 Mar; 45(1):127-8. PubMed ID: 1721659
[No Abstract] [Full Text] [Related]
12. Buspirone, ipsapirone and 1-(2-pyrimidinyl)-piperazine decrease cold-induced thyrotropin secretion in rats.
Broqua P; Baudrie V; Bluet-Pajot MT; Chaouloff F
Eur J Pharmacol; 1991 Nov; 204(2):141-7. PubMed ID: 1687218
[TBL] [Abstract][Full Text] [Related]
13. Effect of acute administration of the 5-HT1A receptor ligand, lesopitron, on rat cortical 5-HT and dopamine turnover.
Ballarín M; Carceller A; Guitart X
Br J Pharmacol; 1994 Oct; 113(2):425-30. PubMed ID: 7530571
[TBL] [Abstract][Full Text] [Related]
14. Effects of gepirone, an aryl-piperazine anxiolytic drug, on aggressive behavior and brain monoaminergic neurotransmission.
McMillen BA; Scott SM; Williams HL; Sanghera MK
Naunyn Schmiedebergs Arch Pharmacol; 1987 Apr; 335(4):454-64. PubMed ID: 2439924
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine.
Berlin I; Chalon S; Payan C; Schöllnhammer G; Cesselin F; Varoquaux O; Puech AJ
Br J Clin Pharmacol; 1995 Mar; 39(3):243-9. PubMed ID: 7619663
[TBL] [Abstract][Full Text] [Related]
16. Dopaminergic effects of buspirone, a novel anxiolytic agent.
Cimino M; Ponzio F; Achilli G; Vantini G; Perego C; Algeri S; Garattini S
Biochem Pharmacol; 1983 Mar; 32(6):1069-74. PubMed ID: 6838654
[TBL] [Abstract][Full Text] [Related]
17. Dopamine receptor antagonism by the novel antianxiety drug, buspirone.
McMillen BA; Matthews RT; Sanghera MK; Shepard PD; German DC
J Neurosci; 1983 Apr; 3(4):733-8. PubMed ID: 6131948
[No Abstract] [Full Text] [Related]
18. Notes on buspirone's mechanisms of action.
Garattini S; Caccia S; Mennini T
J Clin Psychiatry; 1982 Dec; 43(12 Pt 2):19-24. PubMed ID: 6130069
[TBL] [Abstract][Full Text] [Related]
19. Buspirone: chemical profile of a new class of anxioselective agents.
Temple DL; Yevich JP; New JS
J Clin Psychiatry; 1982 Dec; 43(12 Pt 2):4-10. PubMed ID: 6185470
[TBL] [Abstract][Full Text] [Related]
20. A study of the effects of buspirone, BMY 13805, and 1-PP on dopaminergic metabolism in the nucleus accumbens using in vivo voltammetry in freely moving rats.
Louilot A; Le Moal M; Simon H
Life Sci; 1986 Aug; 39(8):685-92. PubMed ID: 2874469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
